** Brokerage Mizuho raises healthcare conglomerate CVS Health's CVS.N PT to $70 from $58, with "outperform" rating
** New PT represents ~14% upside to the stock's close
** Brokerage says CVS is "an attractive investment opportunity given the diversification of its business"
** "We believe CVS' long-term adjusted EPS growth floor is predicated on market share gains and the success of the company's new cost-plus pharmacy reimbursement model" - brokerage adds
** Eighteen of 29 brokerages rate the stock "buy" or higher, eleven "hold"; their median PT is $70.89 - data compiled by LSEG
** CVS has fallen 12.4% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。